Is It Too Late to Jump In on Zentalis?

Zentalis Pharmaceuticals (NASDAQ: ZNTL) stock closed at $52.22 on Friday, 26.4% higher than it did on Thursday. Such spikes are nothing new for this fast-climbing clinical-stage biopharmaceutical company, which specializes in small-molecule cancer drugs. If you had invested $5,000 in the company's IPO in April, when it was selling at $18 a share, you would have $14,505 today.

There's clearly a lot of hype regarding Zentalis, which was founded in 2014 and has its headquarters in New York City with a science center in San Diego.

Image source: Getty Images.

Continue reading

Source Fool.com